Find a Doctor

Refer a Patient
Applied Filters:
Showing 10 of 13 Results
Sort by:

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

NMD Pharma has begun a study of an investigational drug (also known as the "study drug") called NMD670 as a possible treatment for CMT. An investigational drug is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union...

Eligibility: Both men and women 18 years old to 70 years old. Does not accept healthy volunteers.

Default Provider Photo

Mohamed Abdelhakiem, MD

Radiation Oncology

Areas of Expertise

Radiation Oncology

Office Locations

Default Provider Photo

James Allen, MD

Radiation Oncology

Areas of Expertise

Hodgkin's Disease, Pituitary Disorders, Melanoma ... View More

Default Provider Photo

Joseph Bean, MD

Radiation Oncology

Gregory Biedermann, MD headshot

Gregory Biedermann, MD

Radiation Oncology

Areas of Expertise

Melanoma

Default Provider Photo

Mark Bryer, MD

Radiation Oncology

Reed Cope, MD headshot

Reed Cope, MD

Radiation Oncology

Areas of Expertise

Melanoma

Office Locations

Default Provider Photo

William Decker, MD

Radiation Oncology

Harold Johnson, MD headshot

Harold Johnson, MD

Radiation Oncology

Andrew Leiker, MD headshot

Andrew Leiker, MD

Radiation Oncology

Office Locations